• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于模型的仿制药研发与审评:FDA 公开专题研讨会总结

Model-Informed Drug Development and Review for Generic Products: Summary of FDA Public Workshop.

机构信息

Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

出版信息

Clin Pharmacol Ther. 2018 Jul;104(1):27-30. doi: 10.1002/cpt.1065. Epub 2018 Mar 30.

DOI:10.1002/cpt.1065
PMID:29603191
Abstract

On October 2 and 3 , 2017, the US Food and Drug Administration (FDA) hosted a public workshop titled "Leveraging Quantitative Methods and Modeling to Modernize Generic Drug Development and Review." This report summarizes Session 2 of the public workshop: "Model Informed Drug Development and Review for Generic Products." The session focused on the application of quantitative methods and modeling in modernizing the generic drug development and review.

摘要

2017 年 10 月 2 日和 3 日,美国食品和药物管理局(FDA)举办了一场题为“利用定量方法和建模使仿制药开发和审评现代化”的公开研讨会。本报告总结了公开研讨会的第 2 场会议:“用于仿制药的基于模型的药物开发和审评”。本次会议的重点是在使仿制药开发和审评现代化方面应用定量方法和建模。

相似文献

1
Model-Informed Drug Development and Review for Generic Products: Summary of FDA Public Workshop.基于模型的仿制药研发与审评:FDA 公开专题研讨会总结
Clin Pharmacol Ther. 2018 Jul;104(1):27-30. doi: 10.1002/cpt.1065. Epub 2018 Mar 30.
2
Development of Quantitative Comparative Approaches to Support Complex Generic Drug Development.发展定量比较方法以支持复杂仿制药的开发。
AAPS J. 2024 Jan 24;26(1):15. doi: 10.1208/s12248-024-00885-y.
3
Generating Model Integrated Evidence for Generic Drug Development and Assessment.生成用于仿制药开发和评估的模型综合证据。
Clin Pharmacol Ther. 2019 Feb;105(2):338-349. doi: 10.1002/cpt.1282. Epub 2019 Jan 20.
4
Using Mechanistic Modeling Approaches to Support Bioequivalence Assessments for Oral Products.利用机制建模方法支持口服产品的生物等效性评估。
AAPS J. 2024 Jan 24;26(1):19. doi: 10.1208/s12248-024-00886-x.
5
Public Workshop Summary Report on Fiscal Year 2021 Generic Drug Regulatory Science Initiatives: Data Analysis and Model-Based Bioequivalence.2021 财年仿制药监管科学计划公开研讨会总结报告:数据分析和基于模型的生物等效性。
Clin Pharmacol Ther. 2021 Nov;110(5):1190-1195. doi: 10.1002/cpt.2120. Epub 2020 Dec 29.
6
Leveraging Modeling and Simulation to Enhance the Efficiency of Bioequivalence Approaches for Generic Drugs: Highlights from the 2023 Generic Drug Science and Research Initiatives Public Workshop.利用建模和模拟提高仿制药生物等效性方法的效率:2023 年仿制药科学和研究倡议公开研讨会亮点。
AAPS J. 2024 Apr 8;26(3):45. doi: 10.1208/s12248-024-00916-8.
7
Decision Science for Generic Drug Development and Review.仿制药开发与审评的决策科学
J Clin Pharmacol. 2019 Sep;59(9):1249-1251. doi: 10.1002/jcph.929. Epub 2019 May 14.
8
Establishing the suitability of model-integrated evidence to demonstrate bioequivalence for long-acting injectable and implantable drug products: Summary of workshop.建立模型整合证据用于证明长效注射和植入药物产品生物等效性的适宜性:研讨会总结。
CPT Pharmacometrics Syst Pharmacol. 2023 May;12(5):624-630. doi: 10.1002/psp4.12931. Epub 2023 Feb 9.
9
Modeling and simulation of biopharmaceutical performance.生物制药性能的建模与仿真。
Clin Pharmacol Ther. 2014 May;95(5):480-2. doi: 10.1038/clpt.2014.40.
10
United States Food and Drug Administration requirements for approval of generic drug products.美国食品药品监督管理局对仿制药产品批准的要求。
J Clin Psychiatry. 2001;62 Suppl 5:4-9; discussion 23-4.

引用本文的文献

1
Model-Based Bioequivalence Analysis to Assess and Predict the Relative Bioavailability of Valproic Acid Formulations.基于模型的生物等效性分析评估和预测丙戊酸制剂的相对生物利用度。
Eur J Drug Metab Pharmacokinet. 2024 Jul;49(4):507-516. doi: 10.1007/s13318-024-00901-8. Epub 2024 Jun 14.
2
In silico prediction of bioequivalence of atorvastatin tablets based on GastroPlus™ software.基于 GastroPlus™ 软件的阿托伐他汀片剂生物等效性的计算机预测。
BMC Pharmacol Toxicol. 2023 Nov 28;24(1):69. doi: 10.1186/s40360-023-00689-4.
3
A Model-Informed Approach to Accelerate the Clinical Development of Janagliflozin, an Innovative SGLT2 Inhibitor.
一种基于模型的方法加速新型 SGLT2 抑制剂杰纳利鲁肽的临床开发。
Clin Pharmacokinet. 2023 Mar;62(3):505-518. doi: 10.1007/s40262-022-01209-z. Epub 2023 Feb 18.
4
Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making.综述:模型指导药物研发方法在药物研发和监管决策生命周期中的作用。
Pharm Res. 2022 Aug;39(8):1669-1680. doi: 10.1007/s11095-022-03288-w. Epub 2022 May 12.
5
Quantitative methods and modeling to assess COVID-19-interrupted in vivo pharmacokinetic bioequivalence studies with two reference batches.用于评估 COVID-19 中断的体内药代动力学生物等效性研究的两种参比批次的定量方法和建模。
CPT Pharmacometrics Syst Pharmacol. 2022 Jul;11(7):833-842. doi: 10.1002/psp4.12795. Epub 2022 Apr 20.
6
Is It Time to Use Modeling of Cellular Transporter Homeostasis to Inform Drug-Drug Interaction Studies: Theoretical Considerations.是时候利用细胞转运体稳态模型为药物相互作用研究提供信息了:理论思考。
AAPS J. 2021 Aug 25;23(5):102. doi: 10.1208/s12248-021-00635-4.
7
A Quantitative Pharmacology Model of Exosome-Mediated Drug Efflux and Perturbation-Induced Synergy.外泌体介导的药物外排和扰动诱导协同作用的定量药理学模型
Pharmaceutics. 2021 Jun 30;13(7):997. doi: 10.3390/pharmaceutics13070997.
8
Clinical pharmacology applications in clinical drug development and clinical care: A focus on Saudi Arabia.临床药理学在临床药物研发与临床护理中的应用:以沙特阿拉伯为重点
Saudi Pharm J. 2020 Oct;28(10):1217-1227. doi: 10.1016/j.jsps.2020.08.012. Epub 2020 Aug 21.
9
Scientific considerations for global drug development.全球药物研发的科学考量
Sci Transl Med. 2020 Jul 29;12(554). doi: 10.1126/scitranslmed.aax2550.
10
Current trends in drug metabolism and pharmacokinetics.药物代谢与药代动力学的当前趋势。
Acta Pharm Sin B. 2019 Nov;9(6):1113-1144. doi: 10.1016/j.apsb.2019.10.001. Epub 2019 Oct 18.